Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study

Michele Fornaro1
Michael J McCarthy2,3
Domenico De Berardis4
Concetta De Pasquale1
Massimo Tabaton5
Matteo Martino6
Salvatore Colicchio7
Carlo Ignazio Cattaneo8
Emanuela D’Angelo9
Pantaleo Fornaro6

1Department of Formative Sciences, University of Catania, Catania, Italy; 2Department of Psychiatry, Veteran’s Affairs San Diego Healthcare System, University of California San Diego, La Jolla, CA, USA; 3Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, “ASL 4”, Teramo, Italy; 4Department of Internal Medicine and Medical Specialties, University of Genova, Genoa, Italy; 5Department of Neurosciences, Section of Psychiatry, University of Genova, Genoa, Italy; 6Unit of Sleep Medicine, Department of Neuroscience, Catholic University, Rome, Italy; 7National Health System, “ASL 13”, Novara, Italy; 8National Health System, “ASL 3”, Genoa, Italy

Purpose: The circadian rhythm hypothesis of bipolar disorder (BD) suggests a role for melatonin in regulating mood, thus extending the interest toward the melatonergic antidepressant agomelatine as well as type I (acute) or II cases of bipolar depression.

Patients and methods: Twenty-eight depressed BD-II patients received open label agomelatine (25 mg/bedtime) for 6 consecutive weeks as an adjunct to treatment with lithium or valproate, followed by an optional treatment extension of 30 weeks. Measures included the Hamilton depression scale, Pittsburgh Sleep Quality Index, the Clinical Global Impression Scale–Bipolar Version, Young Mania Rating Scale, and body mass index.

Results: Intent to treat analysis results demonstrated that 18 of the 28 subjects (64%) showed medication response after 6 weeks (primary study endpoint), while 24 of the 28 subjects (86%) responded by 36 weeks. When examining primary mood stabilizer treatment, 12 of the 17 (70.6%) valproate and six of the 11 (54.5%) lithium patients responded by the first endpoint. At 36 weeks, 14 valproate treated (82.4%) and 10 lithium treated (90.9%) subjects responded. At 36 weeks, there was a slight yet statistically significant (P = 0.001) reduction in body mass index and Pittsburgh Sleep Quality Index scores compared to respective baseline values, regardless of mood stabilizer/outcome. Treatment related drop-out cases included four patients (14.28%) at week 6 two valproate-treated subjects with pseudo-vertigo and drug-induced hypomania, respectively, and two lithium-treated subjects with insomnia and mania, respectively.

Conclusion: Agomelatine 25 mg/day was an effective and well-tolerated adjunct to valproate/lithium for acute depression in BD-II, suggesting the need for confirmation by future double blind, controlled clinical trials.

Keywords: bipolar disorder type-II, acute bipolar depression, agomelatine, adjunctive treatment

Introduction

Although the Diagnostic and Statistical Manual for Mental Disorders-Fourth Edition (DSM-IV)1 proposes mania as the hallmark of bipolar disorder (BD), depression is the most enduring aspect of the illness,2 requiring intense treatment efforts.3 Moreover, the majority of patients with bipolar depression fail to respond adequately to pharmacotherapy.4 For this reason, novel treatments for bipolar depression are needed, and despite being controversial due to the uneven results reported in acute and long-term follow-up clinical trials, antidepressant medications are commonly used for bipolar depression.5 The antidepressant agomelatine is a norepinephrine and dopamine disinhibitor drug, acting as a 5-HT2C/2B serotonin receptor antagonist and...
MT1/MT2 melatonin receptor agonist proven effective in the treatment of major depressive disorder (MDD).\textsuperscript{6–9} In pilot studies of type I BD (BD-I), agomelatine showed interesting results.\textsuperscript{10,11} Yet, to the best of our knowledge, no equivalent information has been provided about depression in type II BD (BD-II). Because there are important differences between BD-I and BD-II in terms of prevalence, clinical course, and antidepressant treatment implications, the use of agomelatine in the latter condition also warrants investigation.

The conceptualization of BD as a disorder of cycling, possibly based on disturbances in circadian rhythms, has been suggested for centuries. Reports of impaired daily rhythms in “emotional disturbances” date back to Hippocrates, Galen, Aretaeus of Cappadocia [“…vital tone was subject to typical circadian variations”], and later Kraepelin.\textsuperscript{12} However, it was not until after the discovery of melatonin in 1958 that the link between the pineal gland and affective disorders, considered by 17th century Cartesian theorists, found scientific biological support.\textsuperscript{13} More recently, these observations have been articulated into specific hypotheses of circadian rhythms as the bases for mood disorders.\textsuperscript{14,15} Presently, changes in sleep are included in the DSM-IV criteria for major depressive episodes, including those associated with BD, and sleep patterns have been proposed as predictors of manic relapses in BD.\textsuperscript{16} Melatonergic modulation has been shown to be relevant in regulating circadian rhythms and sleep patterns, both in MDD\textsuperscript{17,18} and BD,\textsuperscript{19} and recent evidence suggests an association between 5HTR2C gene polymorphisms and BD.\textsuperscript{20} Therefore, the circadian rhythm system represents a rational target for novel antidepressant medications aiming to address these clinical features of BD,\textsuperscript{21} and due to its unique receptor binding profile, considerable interest has been generated around the use of agomelatine.

The principal aim of this open label pilot study was to assess the efficacy and safety of adjunctive agomelatine pharmacotherapy in the treatment of acute major depression in BD-II. As secondary aims, we examined whether there were differences in sleep and/or body mass associated with agomelatine treatment, and whether any of these outcomes were differentially associated with concomitant lithium or valproate therapy.

**Methods**

**Participants**

Participants aged 18–65 years old were recruited by five experienced physicians between November 2010 and May 2012 through referrals to two main private outpatient practice centers in Italy (Genoa and Pisa). Patients were referred by general practitioners, psychiatrists, or self-referral. All met the DSM-IV criteria for a primary diagnosis of BD-II and a current major depressive episode, assessed by the means of the Structured Clinical Interview for DSM-IV Axis-I Disorders.\textsuperscript{22} Additional inclusion criteria were a Hamilton Depression Rating-Scale 17-item (HAM-D-17)\textsuperscript{23} baseline score ≥ 18; negative history for adrenal, thyroid, or liver diseases; and continuously therapeutic blood levels of lithium or valproate for at least 6 months. Exclusion criteria included (I) lifetime diagnosis of BD-I, schizophrenia, or other psychotic disorders, rapid-cycling or seasonal patterns, history of treatment-resistant depression (defined as non-response to two consecutive treatments of at least 4 weeks each with two different classes of antidepressants), Axis-II comorbidity (including mental retardation), and alcohol/drug use disorders; (II) severe medical comorbidities, including organic brain syndrome, clinically significant drug interactions (eg, ciprofloxacin), pregnancy, nursing, or a woman of childbearing potential who declined the use of an adequate contraceptive; (III) concomitant use of another mood altering medication in the previous 2 weeks, or 4 weeks in the case of fluoxetine (low doses of benzodiazepines [eg, lorazepam ≤ 2.5 mg/day] were allowed during the first 2 weeks); and (III) concomitant psychological treatment. Written informed consent was obtained from all patients prior to enrollment in the study after procedures had been fully explained by a senior study coordinator active in patients’ recruitment and evaluation. A total of 50 subjects were initially screened, and 28 were enrolled in the study (F/M = 17/11). Excluded cases included those with sub-optimal mood stabilizer blood levels (n = 16), those using concomitant pharmacotherapies not allowed by the study protocol (n = 5), and those with a serious medical illness (Gilbert’s syndrome, n = 1). Of the 28 subjects who participated, 17 (60.7%) were on valproate and 11 (39.3%) were taking lithium as their primary mood stabilizer therapy.

**Study design**

The efficacy of agomelatine as an adjunct to valproate (blood levels of 50–125 µg/ml) or lithium (blood levels 0.6–1.1 mmol/L) in the treatment of an acute BD-II major depressive episode was addressed using a 6 week open parallel-group design. No blind assessment or placebo controls were adopted, and the patients were regularly monitored for safety, with clear instructions to report any unexpected adverse events (AEs), including mood changes, to their treating physician at the earliest possible time.
Pharmacotherapy
A fixed dose of agomelatine was used during the entire study (25 mg at bedtime: 9:00–10:00 pm). Higher doses (e.g., 50 mg/day) were excluded due to the preliminary nature of the study according to safety considerations. During the initial period of 6 weeks, a psychiatrist performed clinical evaluations every 2 weeks on each subject. Thereafter, the patients who continued the trial were evaluated every 6 weeks until week 36.

Clinical assessment
Demographic and clinical characteristics were recorded at baseline; the HAM-D-17 was the primary measure of mood. In all cases, “response” was defined as >50% decrease in severity from the baseline HAM-D-17 score. Secondary measures were the Severity and Impression modules of the Clinical Global Impression Scale–Bipolar Version 22 starting at the second week, the Young Mania Rating Scale (YMRS), 23 and the Pittsburgh Sleep Quality Index (PSQI), 24 which is a self-report instrument used to subjectively measure sleep across seven domains: quality, latency, duration, efficiency, disturbances, use of medication, and daytime somnolence. The scale is designed to assess both the initial quality and ongoing comparative measurements of sleep quality, and has a reliability Cronbach’s alpha = 0.83.

At every appointment, an assessment, including general and psychiatric clinical examinations, was performed. These included measurements of blood pressure, heart rate, and body mass index (BMI). Routine laboratory tests included monitoring of liver functioning (safety, including liver enzyme levels, was a secondary endpoint of the study) and blood levels of lithium or valproate. All AEs experienced by participants were recorded at each study visit, based on the clinical judgment of the investigator(s). Due to the explorative nature of the study and safety considerations, whenever an AE occurred (any degree of severity), this was considered grounds for agomelatine discontinuation by the investigators. In these cases, subjects were excluded from further study.

Statistical analysis
The a priori sample size requirement for the study was calculated to be at least 12 in each of the two mood stabilizer groups (≥24 patients in total), based on considerations described previously for non-randomized pilot studies. 25 All statistical analyses were performed using IBM® SPSS®Statistics®v.21.0.0 for Microsoft® Windows®8 Release Preview, Build 8400. Since data followed a normal distribution, they were assessed using the Shapiro-Wilk test. Parametric comparative analysis for demographic, clinical, and course characteristics of the two groups were performed using a Student’s two-tailed t-test for the continuous variables, and χ² analysis for categorical variables, performing bivariate correlation analysis for selected metrics. Significance was set at P < 0.05. Intent to treat analysis was performed for efficacy in those patients who took at least one capsule of study medication and had at least one valid post-baseline efficacy evaluation, either on the study medication or within 3 days of drug discontinuation.

Results
Patient characteristics
Baseline demographic and clinical characteristics of the study subjects are shown in Table 1. There were no significant differences in patient characteristics between the lithium and valproate treated subjects, although some numerical differences may have led to statistical significance with a larger, “non-pilot,” sample size. All were diagnosed with BD-II, but many had secondary psychiatric disorders. Inter-rater reliability on the DSM-IV diagnosis indicated substantial agreement among the raters (Cohen’s κ = 0.75 [P < 0.0001], 95% CI = 0.65–0.37). By adopting a conservative definition of severe depression of HAM-D-17 scores > 28 26, it was found that five patients (17.9%) were severely depressed at study entry (n = 4 [23.5%] for valproate and n = 1 [9.1%] for lithium).

Primary outcomes
Using intent to treat analysis, 12 of the 17 valproate treated (70.6%) and 6 of the 11(54.5%) lithium treated patients demonstrated clinical response to agomelatine augmentation at the 6 week primary study endpoint. Six valproate and one lithium treated patients (25% of the total) responded as early as the second week of treatment. Secondary analyses conducted at the 6 week assessment are shown in Table 2. At the 36 week endpoint, 14 of the 17 (82.4%) valproate treated and 10 of the 11 (90.9%) lithium treated subjects had a clinical response.

Secondary outcomes
PISQ scores were significantly reduced after 6 weeks compared to baseline (t = 6.738 [27]; P < 0.001), and PISQ scores remained lower at week 36 (t = 3.777 [27]; P = 0.001). The PISQ reduction was similar in both the valproate and lithium groups, and occurred independently of therapeutic response at weeks 6 or 36. At week 36, a slight yet statistically significant (t = 3.777; df = 27; P < 0.001) reduction in BMI score was...
observed in the intent to treat population (24.32 ± 2.26 vs baseline 25.33 ± 2.62) regardless of the primary mood stabilizer treatment. Specifically, mean BMI scores at week 36 were 24.73 ± 2.12 among lithium treated subjects and 24.66 ± 2.85 among valproate treated subjects and 24.82 ± 2.62 regardless of the primary mood stabilizer treatment. Specifically, mean BMI scores at week 36 were 24.73 ± 2.12 among lithium treated subjects and 24.66 ± 2.85 among valproate treated subjects and 24.82 ± 2.62 regardless of the primary mood stabilizer treatment. Specifically, mean BMI scores at week 36 were 24.73 ± 2.12 among lithium treated subjects and 24.66 ± 2.85 among valproate treated subjects.

Table 1 Baseline characteristics of the patients included in the study

<table>
<thead>
<tr>
<th></th>
<th>Included set N = 28</th>
<th>Agomelatine + valproate group N = 17 (60.7%)</th>
<th>Agomelatine + lithium group N = 11 (39.3%)</th>
<th>F or χ² (df = 2)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex F/M</td>
<td>17/11</td>
<td>9/8</td>
<td>8/3</td>
<td>0.295 (1)</td>
<td>ns</td>
</tr>
<tr>
<td>Age in years, Me (SD): (range)</td>
<td>41.29 ± 13.60</td>
<td>41.94 ± 13.94</td>
<td>40.27 ± 13.66</td>
<td>0.174</td>
<td>ns</td>
</tr>
<tr>
<td>Age at first diagnosis of BD, mean (SD): (range)</td>
<td>26.21 ± 9.97</td>
<td>25.58 ± 7.68</td>
<td>27.18 ± 12.76</td>
<td>1.539 (26)</td>
<td>ns</td>
</tr>
<tr>
<td>BMI score, mean (SD)</td>
<td>25.33 ± 2.62</td>
<td>25.17 ± 2.85</td>
<td>25.59 ± 2.33</td>
<td>0.610 (26)</td>
<td>ns</td>
</tr>
<tr>
<td>Positive family history for BD-II, N (%)</td>
<td>10 (35.7%)</td>
<td>6 (60%)</td>
<td>4 (40%)</td>
<td>0.003 (1)</td>
<td>ns</td>
</tr>
<tr>
<td>First episode polarity (depressive/hypomanic)</td>
<td>24 (85.7%)/4 (14.3%)</td>
<td>14 (82.4%)/3 (17.6%)</td>
<td>10 (90.9%)/1 (9.1%)</td>
<td>0.399 (1)</td>
<td>ns</td>
</tr>
<tr>
<td>Reported number of depressive episodes (previous 5 years)*</td>
<td>None, N = 16 (57.1%)</td>
<td>None, N = 10 (35.7%)</td>
<td>None, N = 9 (52.9%)</td>
<td>0.591 (2)</td>
<td>ns</td>
</tr>
<tr>
<td></td>
<td>≤3, N = 10 (35.7%)</td>
<td>≤3, N = 7 (41.2%)</td>
<td>≤3, N = 7 (41.2%)</td>
<td>0.591 (2)</td>
<td>ns</td>
</tr>
<tr>
<td></td>
<td>≥4, N = 2 (7.1%)</td>
<td>≥4, N = 1 (5.9%)</td>
<td>≥4, N = 1 (5.9%)</td>
<td>0.591 (2)</td>
<td>ns</td>
</tr>
<tr>
<td>Duration of current depressive episode days (SD): (range)</td>
<td>25.64 ± 18.54; (14–90)</td>
<td>26.18 ± 21.59; (14–90)</td>
<td>24.82 ± 13.47; (14–60)</td>
<td>10.781 (10)</td>
<td>ns</td>
</tr>
<tr>
<td>HAM-D-17 score (SD): (range)</td>
<td>25.86 ± 3.19; (19–31)</td>
<td>26.53 ± 2.76; (21–31)</td>
<td>24.82 ± 3.65; (19–31)</td>
<td>14.374 (10)</td>
<td>ns</td>
</tr>
<tr>
<td>YMRS score (SD)</td>
<td>3.46 ± 1.57</td>
<td>3.41 ± 1.43</td>
<td>3.54 ± 1.37</td>
<td>3.544 (6)</td>
<td>ns</td>
</tr>
<tr>
<td>PSQI score (SD)</td>
<td>11.39 ± 5.31</td>
<td>10.70 ± 4.62</td>
<td>12.45 ± 6.63</td>
<td>12.453 (12)</td>
<td>ns</td>
</tr>
<tr>
<td>CGI-BP-S (SD)</td>
<td>4.36 ± 1.37</td>
<td>3.94 ± 1.14</td>
<td>5 ± 1.48</td>
<td>5.372 (6)</td>
<td>ns</td>
</tr>
<tr>
<td><strong>Lifetime axis-I co-morbidity, N (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Generalized anxiety disorder</td>
<td>6 (21.4%)</td>
<td>4 (23.5%)</td>
<td>2 (18.2%)</td>
<td>0.113 (1)</td>
<td>ns</td>
</tr>
<tr>
<td>Obsessive-compulsive disorder</td>
<td>7 (25%)</td>
<td>3 (17.6%)</td>
<td>4 (36.4%)</td>
<td>1.248 (1)</td>
<td>ns</td>
</tr>
<tr>
<td>Panic disorder</td>
<td>5 (17.9%)</td>
<td>3 (17.6%)</td>
<td>2 (18.2%)</td>
<td>0.001 (1)</td>
<td>ns</td>
</tr>
<tr>
<td>Specific phobias</td>
<td>8 (26.6%)</td>
<td>4 (23.3%)</td>
<td>4 (36.4%)</td>
<td>0.539 (1)</td>
<td>ns</td>
</tr>
<tr>
<td>Impulse control disorder</td>
<td>4 (14.3%)</td>
<td>3 (17.6%)</td>
<td>1 (9.1%)</td>
<td>0.399 (1)</td>
<td>ns</td>
</tr>
<tr>
<td>Anorexia nervosa</td>
<td>1 (3.6%)</td>
<td>1 (5.9%)</td>
<td>0</td>
<td>0.671 (1)</td>
<td>ns</td>
</tr>
<tr>
<td>Bulimia nervosa</td>
<td>3 (10.7%)</td>
<td>2 (11.8%)</td>
<td>1 (9.1%)</td>
<td>0.050 (1)</td>
<td>ns</td>
</tr>
<tr>
<td>Binge eating disorder</td>
<td>4 (14.3%)</td>
<td>3 (17.6%)</td>
<td>1 (9.1%)</td>
<td>0.399 (1)</td>
<td>ns</td>
</tr>
</tbody>
</table>

Notes: For χ² and relative, P values refer to the comparison between the two groups, not versus the whole sample (+valproate vs +lithium). *Age at first diagnosis of BD” may differ from age at first medical consultation for major depression or from actual age of onset of BD. **Current MDE excluded.

Abbreviations: BMI, body mass index; CGI-BP-I/S, Clinical Global Impression/Severity scales for Bipolar Disorder; HAM-D-17, Hamilton Depression Rating-Scale 17-item; MDE, major depressive episode; PSQI, Pittsburgh Sleep Quality Index; SD, standard deviation; YMRS, Young Mania Rating Scales.

Adverse events
Four patients (14.28% of the total) dropped out due to a treatment-related AE by week 6. In the valproate group, these

Table 2 Comparison of clinical measures at week-6 of the study (last post-baseline value)

<table>
<thead>
<tr>
<th></th>
<th>Included set N = 28</th>
<th>+valproate group N = 17 (60.7%)</th>
<th>+lithium group N = 11 (39.3%)</th>
<th>F or χ² (df = 2)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>HAM-D-17 mean score (SD)</td>
<td>10.71 (4.52)</td>
<td>10.23 (3.99)</td>
<td>11.45 (5.35)</td>
<td>11.58 (12)</td>
<td>ns</td>
</tr>
<tr>
<td>YMRS mean score (SD)</td>
<td>7.89 (5.14)</td>
<td>6.94 (3.38)</td>
<td>9.36 (7.01)</td>
<td>10.531 (8)</td>
<td>ns</td>
</tr>
<tr>
<td>BMI score, mean (SD)</td>
<td>25.27 (1.26)</td>
<td>25.59 (3.21)</td>
<td>24.77 (3.43)</td>
<td>16.610 (15)</td>
<td>ns</td>
</tr>
<tr>
<td>CGI-BP-S mean (SD)</td>
<td>4.18 (1.28)</td>
<td>3.82 (1.13)</td>
<td>4.73 (1.35)</td>
<td>4.742 (5)</td>
<td>ns</td>
</tr>
<tr>
<td>CGI-BP-I mean (SD)</td>
<td>2.78 (1.64)</td>
<td>2.88 (1.87)</td>
<td>2.64 (1.29)</td>
<td>2.306 (6)</td>
<td>ns</td>
</tr>
<tr>
<td>PSQI mean (SD)</td>
<td>4.61 (1.42)</td>
<td>4.88 (1.41)</td>
<td>4.18 (1.40)</td>
<td>3.835 (5)</td>
<td>ns</td>
</tr>
</tbody>
</table>

Abbreviations: BMI, body mass index; CGI-BP-I/S, Clinical Global Impression/Severity scales for Bipolar Disorder; HAM-D-17, Hamilton Depression Rating-Scale 17-item; PSQI, Pittsburgh Sleep Quality Index; SD, standard deviation; YMRS, Young Mania Rating Scales.
Figure 1 Trend of different rating and clinical parameters at weeks 6 and 36 between the two groups.

**Note:** While the figure fails to show any substantial differences between groups, this highlights the fact that the effect of agomelatine add-on therapy was substantially maintained within week 6 and week 36, independent of the ongoing mood stabilizer treatment.

**Abbreviations:** BMI, body mass index; CGI-BP-I/S, Clinical Global Impression/Severity scales for Bipolar Disorder; HAM-D-17, Hamilton Depression Rating-Scale 17-item; PSQI, Pittsburgh Sleep Quality Index; YMRS, Young Mania Rating Scales.

Discussion

Overview and limits of the study

Our results suggest that adjunctive agomelatine may be useful in the treatment of acute depression in BD-II. During both the short- and longer-term periods of the trial, agomelatine treatment was associated with improvements in depression and sleep quality and was well tolerated.

Nonetheless, the study was limited by several important factors that warrant discussion, especially in light of the potential “publication and outcome reporting” biases that have arisen regarding randomized controlled studies involving agomelatine in the treatment of MDD.

Additionally, the pharmacodynamics of agomelatine need to be better characterized in human samples. In fact, by inhibiting 5-HT2C receptors, agomelatine secondarily increases norepinephrine and dopamine in the frontal cortex of the brain of animals, while the drug binding and coupling profiles of h5-HT2B and h5-HT2C receptors are similar, and agomelatine also blocked 5-HT-induced [3H]PI depletion at h5-HT2B sites. However, 5-HT2B receptors are poorly represented in the central nervous system, wherein their functional significance remains substantially obscure.

Due to safety reasons and the preliminary nature of the study, raters also participated in the clinical management and were therefore not blind to treatment assignments (“measurement bias”). Moreover, because agomelatine is not yet supplied for free by the National Health System in Italy (unlike many medications), this naturalistic study may suffer from an additional selection bias, favoring recruitment...
of patients who were more financially stable and/or motivated for treatment, potentially influencing both the drop-out rate and medication adherence (“under/over-reporting bias”), especially in the optional 30 week extension period. Despite these limitations, our results should stimulate further investigation of agomelatine and BD-II.

On the other hand, since the ultimate goal of treatment in “acute” bipolar depression should be establishing long-term mood stability,12 the lack of additional follow up, ideally beyond 52 weeks,11 needs to be noted, although very few pilot studies would indeed follow this criterion. However, it is worthy of notice that during both the acute and extension periods of the trial, adjunctive agomelatine treatment was associated with improvement in depression, with favorable safety and tolerability profiles, including sensitive issues such as liver (there was no clinically relevant enzyme modification within the trial) and sexual function,29,33,34 although these latter outcomes were not assessed by ad hoc instruments, and improvement of subjective sleep quality – when initially impaired – was not assessed by actigraphic techniques or by other objective neurophysiological measurements due to the very preliminary nature of the study, whereas lithium or valproate may have contributed both to the antidepressant response and, possibly, to modulation of MT1/MT2 melatonergic receptors as already documented in animal models.35,36

Finally, the fact that the mean duration of depression was less than 4 weeks (with a lower range of 2 weeks) cannot exclude the chance of spontaneous improvement due to the natural course of depression for those subjects judged as “responders”; equally, the eventual predictive role of anxious co-morbidity (when present) could not be evinced at this time due to the small sample size and methodological limits of this preliminary study, although agomelatine has been anecdotally reported to have a promising modulating role in anxious disorders.37–43

Agomelatine, sleep, and depression

The effects of agomelatine on sleep have already been documented by different studies on MDD samples. Among others, a comparative study with venlafaxine highlighted a statistically significant improvement of sleep with agomelatine,44 a faster improvement of the “circadian rest-activity cycle” compared to sertraline,45 and a better rapid eye movement profile – but not short wave sleep profile, possibly due to 5-HT2C antagonism in comparison to escitalopram,46 although the degree to which 5-HT2C receptor antagonism explains or contributes to the antidepressant or sleep effect of agomelatine has been questioned in humans.47

Sleep disturbances are a core aspect of BD and may often predict subsequent manic switch.48 In our study and in others, agomelatine led to sustained subjective improvements in sleep quality in association with either lithium or valproate, beginning as early as 2 weeks into treatment. The concomitant use of benzodiazepines during the first 2 weeks may have influenced these results, but is unlikely to account for the effect since only a minority patients used these medications (n = 3/28; 10.7%), and no patients used them beyond the second week. Improved sleep quality may have important clinical implications for BD-II, but may not necessarily improve mood.49 While insomnia has been reported as a major predictor of depression,50 abnormalities in sleep architecture, including disturbances of sleep consolidation, slow-wave sleep, and rapid eye movement sleep are common during antidepressant treatments, suggesting sleep quality and mood state are dissociable.51,52 Paradoxically, four patients (14.3%) experienced insomnia while taking agomelatine. This problem was effectively managed after exclusion from the study by switching the time of agomelatine administration from bedtime to early morning, without any subsequent manic switch. While not described in previous trials, this unexpected insomnia may be related to circadian phase abnormalities associated with depression. In seasonal depression, most patients are thought to be phase delayed and respond to the phase advancing effects of evening melatonin. In contrast, −30% may be phase advanced.53 In these latter cases, evening melatonin receptor stimulation may lead to a worsening of the circadian abnormality by further advancing phase, perhaps disrupting sleep onset and causing nighttime insomnia. If these findings generalize to bipolar depression, among the minority of subjects with advanced phase, morning agomelatine would correct the abnormality by delaying phase to a more optimal time.

Adverse events and manic switch

While relatively few in number, our study did have AEs to report, including four mood switches to (hypo-) mania. The rate of manic/hypomanic switch was lower than expected based on previous clinical experience with other antidepressants added to mood stabilizers in the treatment of acute depression in BD-II, yet was still remarkable compared to other established antidepressants.54 Nonetheless, the profile of agomelatine with regard to manic switching is consistent with preliminary reports from BD-I;55 since the safety of antidepressants in bipolar depression is of great interest in modern clinical psychiatry, further research on this issue is needed for agomelatine to reliably compare corresponding...
data coming from controlled trials on other antidepressants, ideally looking at long-term treatment compliance and stability.\textsuperscript{35}

The occurrence of “pseudo-vertigo” (dizziness not involving a sense of rotation, which is common in the course of panic disorders, hyperventilation, and orthostatic hypotension) in three patients was another unexpected AE that was encountered. Of note, a previous case report suggested an interaction between agomelatine and the melatonergic neurons of the cerebellum in a minority of sensitive individuals.\textsuperscript{38} Larger studies are required to determine the rate of AE associated with this problem.

**Implications for the circadian rhythm hypothesis of BD**

With the associated disruptions in sleep and daily activity cycles, circadian rhythm abnormalities have been proposed to play a role in the etiology of mood disorders, including BD. Both lithium and valproate, the mood stabilizers used in our study, have effects on circadian rhythms,\textsuperscript{56–58} and genetic variants in clock genes have been associated with lithium response.\textsuperscript{59} BD patients have been reported to be particularly sensitive to environmental events,\textsuperscript{60,61} a feature that has also been associated with circadian instability,\textsuperscript{62} suggesting that biological rhythms play a critical role in the emotional dysregulation at the center of BD.\textsuperscript{59,63,64} Central to the circadian effects on mood is the availability of light. Differential outcomes in antidepressant response are associated with specific changes in retinal physiology, suggesting that proper timing of light input into the central nervous system may be an important aspect of antidepressant response.\textsuperscript{65}

In this context, it is interesting to consider the implications of our agomelatine findings with respect to the circadian clock hypothesis of mood disorders. We found changes in sleep quality and BMI, the latter presumably reflecting differences in dietary intake and/or motor activity. It is interesting to note that regardless of the use of drugs that affect the clock in distinct ways (lithium and valproate), the effects of agomelatine on rhythmically influenced behaviors did not differ by the concomitant mood stabilizer. Of interest, previous reports have described melatonergic neurons outside the central nervous system, including those in the gastrointestinal tract, that are influenced both by light/dark cycles and environmental stresses.\textsuperscript{66–69} Collectively, these findings lend support to the supposed interaction between melatonergic regulation on mood and the “gut-clock”.\textsuperscript{70} If further evidence supports the hypothesis that agomelatine functions as core “rhythm regulator,”\textsuperscript{71} it could play a therapeutic role for those BD patients with prominent imbalances in eating rhythms, and may extend the concept of rhythm disturbances in mood disorder to include feeding behavior and metabolic activity in addition to sleep/wake behavior.\textsuperscript{72–75} This could be in marked contrast to standard antidepressants, with their propensity toward causing weight gain via serotonergic stimulation of 5-HT\textsubscript{2A} receptors rather than selective antagonism of 5-HT\textsubscript{2C}.\textsuperscript{5,51,76,77} It will be of interest in the future to determine whether agomelatine affects excessive or atypical eating behaviors in the context of depression, especially in the view that animal studies have reported that 5-HT\textsubscript{2B} agonists concur with hyperphagia and reduce grooming in rodents,\textsuperscript{78} whereas stimulation of 5-HT\textsubscript{2B} sites exerts actions in animal peripheral tissues, especially in development. However, there is no evidence for a functional effect of antagonists at these sites\textsuperscript{79} and agomelatine is yet to be characterized in this regard in human samples.

**Concluding remarks**

Adjunctive agomelatine treatment with lithium or valproate in the acute phase of BD-II major depression led to substantial positive results in our preliminary open label trial. Large double-blind randomized controlled studies are warranted and will be essential to providing more definitive evidence of the efficacy, safety, and optimal dose-range profile compared to MDD usage.\textsuperscript{80}

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


Agomelatine adjunct in acute BD-II depression

Neuropsychiatric Disease and Treatment

Dovepress

Neuropsychiatric Disease and Treatment is an international, peer-reviewed journal of clinical therapeutics and pharmacology focusing on concise rapid reporting of clinical or preclinical studies on a range of neuropsychiatric and neurological disorders. This journal is indexed on PubMed Central, the ‘PsychINFO’ database and CAS.

Publish your work in this journal

Neuropsychiatric Disease and Treatment is an international, peer-reviewed journal of clinical therapeutics and pharmacology focusing on concise rapid reporting of clinical or preclinical studies on a range of neuropsychiatric and neurological disorders. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.